Completion of Financing and Total Voting Rights

LONDON and SALT LAKE CITY, 15 April 2024 - Further to the announcement on 8 April 2024, Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the sale and purchase of 2,666,667 ordinary shares of £0.0025 each ("Ordinary Shares") to DB Capital Partners Healthcare, L.P. ("DB Capital") for an amount of $1.0 million (the "Initial Tranche Shares") is expected to complete tomorrow.

DB Capital has the option to purchase a subsequent tranche of Ordinary Shares at its discretion. Both tranches are priced at $0.75 per NASDAQ American Depositary Shares ("ADSs") ($0.375 per Ordinary Share). The aggregate total amount for both tranches, if the option is fully exercised, is expected to be up to $4 million in total financing.

An application has been made to London Stock Exchange plc for admission of the Initial Tranche Shares to trading on AIM. It is expected that admission of the Initial Tranche Shares to trading on AIM will become effective on, or around, 8 a.m. UK time on 16 April 2024 ("Admission"). The Initial Tranche Shares will rank pari passu with the existing Ordinary Shares of the Company.

Total Voting Rights

Following allotment and issue of the Initial Tranche Shares, the Company's enlarged issued ordinary share capital will be 126,219,016. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Capitalised terms used but not defined in this announcement have the meanings given to them in the announcement dated 8 April 2024, unless the context provides otherwise.